Christopher Jones

Dr. Christopher Jones


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2015 in BMC Medicine
Verified
Journal Article
Open access
PDF file
CJChristopher Jones
Christopher Jones
LKLukas G. Keil
Lukas G. Keil
WHWesley C. Holland
Wesley C. Holland
MCMelissa C. Caughey
Melissa C. Caughey
TPTimothy F. Platts-Mills
Timothy F. Platts-Mills
Clinical trial registries can improve the validity of trial results by facilitating comparisons between prospectively planned and reported outcomes. Previous reports on the frequency of planned and reported outcome inconsistencies have reported widely discrepant results. It is unknown whether these discrepancies are due to differences between the included trials, or to methodological differences between studies. We aimed to systematically review the prevalence and nature of discrepancies between registered and published outcomes among clinical trials. We searched MEDLINE via PubMed, EMBASE, and CINAHL, and checked references of included publications to identify studies that compared trial outcomes as documented in a publicly accessible clinical trials registry with published trial outcomes. Two authors independently selected eligible studies and performed data extraction. We present summary data rather than pooled analyses owing to methodological heterogeneity among the included studies. Twenty-seven studies were eligible for inclusion. The overall risk of bias among included studies was moderate to high. These studies assessed outcome agreement for a median of 65 individual trials (interquartile range [IQR] 25–110). The median proportion of trials with an identified discrepancy between the registered and published primary outcome was 31 %; substantial variability in the prevalence of these primary outcome discrepancies was observed among the included studies (range 0 % (0/66) to 100 % (1/1), IQR 17–45 %). We found less variability within the subset of studies that assessed the agreement between prospectively registered outcomes and published outcomes, among which the median observed discrepancy rate was 41 % (range 30 % (13/43) to 100 % (1/1), IQR 33–48 %). The nature of observed primary outcome discrepancies also varied substantially between included studies. Among the studies providing detailed descriptions of these outcome discrepancies, a median of 13 % of trials introduced a new, unregistered outcome in the published manuscript (IQR 5–16 %). Discrepancies between registered and published outcomes of clinical trials are common regardless of funding mechanism or the journals in which they are published. Consistent reporting of prospectively defined outcomes and consistent utilization of registry data during the peer review process may improve the validity of clinical trial publications.

1 October 2018 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
CJChristopher Jones
Christopher Jones
ZCZachary Christman
Zachary Christman
CSChristopher M. Smith
Christopher M. Smith
MSMichelle R. Safferman
Michelle R. Safferman
MSMatthew Salzman
Matthew Salzman
RHRachel Haroz
Rachel Haroz

11 October 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
CJChristopher Jones
Christopher Jones
MSMichelle R Safferman
Michelle R Safferman
AAAmanda C Adams
Amanda C Adams
TPTimothy F Platts-Mills
Timothy F Platts-Mills
Objectives To determine the accuracy of the recruitment status listed on ClinicalTrials.gov as compared with the actual trial status. Design Cross-sectional analysis. Setting Random sample of interventional phase 2–4 clinical trials registered between 2010 and 2012 on ClinicalTrials.gov. Primary outcome measure For each trial which was listed within ClinicalTrials.gov as ongoing, two investigators performed a comprehensive literature search for evidence that the trial had actually been completed. For each trial listed as completed or terminated early by ClinicalTrials.gov, we compared the date that the trial was actually concluded with the date the registry was updated to reflect the study’s conclusion status. Results Among the 405 included trials, 92 had a registry status indicating that study activity was either ongoing or the recruitment status was unknown. Of these, published results were available for 34 (37%). Among the 313 concluded trials, the median delay between study completion and a registry update reflecting that the study had ended was 141 days (IQR 48–419), with delays of over 1 year present for 29%. In total, 125 trials (31%) either had a listed recruitment status which was incorrect or had a delay of more than 1 year between the time the study was concluded and the time the registry recruitment status was updated. Conclusions At present, registry recruitment status information in ClinicalTrials.gov is often outdated or wrong. This inaccuracy has implications for the ability of researchers to identify completed trials and accurately characterise all available medical knowledge on a given subject.

17 September 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
CJChristopher Jones
Christopher Jones
AWAshley L Woodford
Ashley L Woodford
TPTimothy F Platts-Mills
Timothy F Platts-Mills
Objectives To characterise current COVID-19-related research activities. Design Cross-sectional analysis. Setting Clinical trials registered with ClinicalTrials.gov testing interventions relevant to COVID-19. Data sources ClinicalTrials.gov was searched for COVID-19 and related terms to identify trials registered between 1 December 2019 and 1 May 2020 that test interventions related to the COVID-19 pandemic. Main outcome measures We classified trials according to intervention type, and report key trial characteristics including recruitment status, location, funder type, target enrolment number, intervention model (single group, randomised or sequential assignment) and projected completion date. Results Of the 630 identified clinical trials related to COVID-19, 509 (81%) involved the study of drugs or biological agents. Of these trials of drugs and biologics, 305 (60%) use an open-label design, 43 (8%) are single blinded (participant only) and 161 (32%) are double blinded (participant and investigator). 94 (18%) of the drug/biological trials are non-randomised. Either hydroxychloroquine or chloroquine is administered as part of the study protocol in 152 (30%) of the drug/biological trials. The total planned enrolment for these hydroxychloroquine/chloroquine trials is over 200 000 participants, which represents 65% of the total planned enrolment for all registered trials of drugs or biologics. There are also at least 25 registered trials of azithromycin (n=53), convalescent plasma (n=38), lopinavir/ritonavir (n=30), stem cell treatments (n=29) and tocilizumab (n=25). 142 trials were registered in the first 3 months of 2020, and 488 trials were registered between 1 April and 1 May 2020. Conclusions These findings demonstrate a robust research response to the COVID-19 pandemic, though many of the currently planned and ongoing trials focus on a small number of potential therapies, and many also lack essential design features and power necessary to provide accurate treatment effect estimates.

1 November 2016 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
BBBrad S. Bendesky
Brad S. Bendesky
KHKrystal Hunter
Krystal Hunter
MKMichael A. Kirchhoff
Michael A. Kirchhoff
CJChristopher Jones
Christopher Jones

24 November 2016 in BMJ Open
Verified
Journal Article
Open access
PDF file
CJChristopher Jones
Christopher Jones
VBValerie A Braz
Valerie A Braz
SMStephen M McBride
Stephen M McBride
BRBrian W Roberts
Brian W Roberts
TPTimothy F Platts-Mills
Timothy F Platts-Mills
Objectives Previous studies have shown that a majority of patients cite altruistic motives, such as contributing to generalisable medical knowledge, as factors motivating clinical trial participation. We sought to examine the impact of making trial results publicly available on patients' willingness to participate in clinical research. Design Cross-sectional analysis using a questionnaire developed by a panel with expertise in publication bias, informed consent and survey design. Setting A single urban, academic emergency department (ED) in the Northeastern USA. Participants 799 ED patients. Outcome Measures We assessed (1) participants' attitudes towards clinical trial participation, and (2) the impact of whether study results would eventually be made publicly available or not on willingness to participate in a trial. Results Of 799 patients surveyed, 36% (95% CI 32% to 39%) reported that they would generally like to participate in a trial, and another 50% (95% CI 47% to 54%) reported that they would consider participation depending on study details. For the majority of participants, the publication of trial results was either important (36%; 95% CI 33% to 40%) or very important (48%; 95% CI 44% to 51%). Most (63%; 95% CI 59% to 66%) reported they would be less likely to participate in a trial if investigators had not publicly released results from a prior study. Additionally, 85% (95% CI 82% to 87%) felt that it was important or very important to receive information about the publication track record of sponsors and investigators during the informed consent process. Conclusions The majority of patients in this sample would consider participation in a clinical trial. Patients value the public release of trial results, and believe that the informed consent process should address the possibility of non-publication.